Cerebrotendinous xanthomatosis - Possible higher prevalence than previously recognized

被引:78
作者
Lorincz, MT
Rainier, S
Thomas, D
Fink, JK
机构
[1] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[2] Ann Arbor Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI USA
关键词
D O I
10.1001/archneur.62.9.1459
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cerebrotendinous xanthomatosis (CTX) is a rare but treatable neurodegenerative disorder caused by 27-sterol hydroxylase (CYP27) deficiency. Objective: To describe clinical features and results of genetic analysis in a family with CTX. Design: Case report. Setting: University hospital. Subjects: A 54-year-old woman with CTX, her family members, and 115 white control subjects. Main Outcome Measures: Results of clinical evaluation and magnetic resonance imaging of the brain in the affected subject; results of mutation analysis of the CYP27 coding sequence in the patient, her parents, and the control subjects. Results: The proband and her affected sibling had classic features of CTX, including presenile cataracts, tendon xanthomas, diarrhea, and a complex neurodegenerative disorder. They were somewhat atypical, however, because their cataracts were congenital, cognitive impairment had been noted in childhood, and the white matter involvement was more severe than usual. The proband was shown to be homozygous for CYP27 mutation R362C. Similar analysis of 115 control subjects identified 1 subject who was a heterozygous carrier for this same CYP27 mutation. Conclusions: The prevalence of CTX due to CYP27 mutation R362C alone is approximately 1 per 50 000 among white individuals. Although the disorder is rare, this incidence is substantially greater than previously recognized. Greater awareness of CTX is important because specific treatment is available.
引用
收藏
页码:1459 / 1463
页数:5
相关论文
共 15 条
  • [1] Cerebrotendinous xanthomatosis:: The spectrum of imaging findings and the correlation with neuropathologic findings
    Barkhof, F
    Verrips, A
    Wesseling, P
    van der Knaap, MS
    van Engelen, BGM
    Gabreëls, FJM
    Keyser, A
    Wevers, RA
    Valk, J
    [J]. RADIOLOGY, 2000, 217 (03) : 869 - 876
  • [2] BERGINER V, 1997, MOL GENETIC BASIS NE, P1051
  • [3] OSTEOPOROSIS AND INCREASED BONE-FRACTURES IN CEREBROTENDINOUS XANTHOMATOSIS
    BERGINER, VM
    SHANY, S
    ALKALAY, D
    BERGINER, J
    DEKEL, S
    SALEN, G
    TINT, GS
    GAZIT, D
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (01): : 69 - 74
  • [4] GENETICS OF CEREBROTENDINOUS XANTHOMATOSIS (CTX) - AN AUTOSOMAL RECESSIVE TRAIT WITH HIGH GENE-FREQUENCY IN SEPHARDIM OF MOROCCAN ORIGIN
    BERGINER, VM
    ABELIOVICH, D
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 1981, 10 (02): : 151 - 157
  • [5] LONG-TERM TREATMENT OF CEREBROTENDINOUS XANTHOMATOSIS WITH CHENODEOXYCHOLIC ACID
    BERGINER, VM
    SALEN, G
    SHEFER, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (26) : 1649 - 1652
  • [6] CALI JJ, 1991, J BIOL CHEM, V266, P7779
  • [7] Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis
    De Stefano, N
    Dotti, MT
    Mortilla, M
    Federico, A
    [J]. BRAIN, 2001, 124 : 121 - 131
  • [8] Cerebrotendinous xanthomatosis: Heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings
    Dotti, MT
    Rufa, A
    Federico, A
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2001, 24 (07) : 696 - 706
  • [9] Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum
    Dotti, MT
    Mondillo, S
    Plewnia, K
    Agricola, E
    Federico, A
    [J]. JOURNAL OF NEUROLOGY, 1998, 245 (11) : 723 - 726
  • [10] Idouji K, 1991, Rinsho Shinkeigaku, V31, P402